PROFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Profound Medical Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$5.86−0.15 (-2.50%)

Close on Oct 19, 2026

Market cap: $213.01M
P/E (TTM): 4.2
Dividend yield: –

Profound Medical Corp. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2019-01-01
Revenue	16	11	7.20	6.68	6.87	7.30	4.17	–
Cost of Revenue	4.71	3.64	2.89	3.66	3.92	3.83	1.78	–
Gross Profit	11	7.04	4.31	3.02	2.95	3.47	2.39	–
Research & Development	21	17	14	15	15	9.91	9.40	–
Selling, General & Admin	32	23	19	–	–	–	–	–
Selling & Marketing	–	–	9.45	8.47	7.65	4.86	2.10	–
Advertising Expenses	3.86	4.48	3.35	–	–	–	–	–
Operating Expenses	53	40	33	35	33	22	17	–
Operating Income	-41	-33	-29	-32	-30	-19	-15	–
Interest Expense	0.39	0.60	0.15	0.29	0.45	2.71	0.17	–
Other Non-Operating Income	-1.06	5.24	0.20	–	–	–	–	–
Pretax Income	-42	-28	-28	-28	-31	-22	-15	–
Income Tax Expense	0.25	0.00	-0.13	0.29	0.11	0.05	0.15	–
Net Income incl. Noncontrolling Interests	-43	-28	-28	-29	-31	-22	-15	–
Net Income	-43	-28	-28	–	–	–	–	–
Net Income to Common	43	28	–	–	–	–	–	–
EPS (Basic)(per share)	1.41	1.12	1.34	1.38	1.50	1.25	1.37	–
EPS (Diluted)(per share)	1.41	1.12	1.34	1.38	1.50	1.25	1.37	–
Shares Outstanding (Basic, Weighted)(shares)	30	25	21	21	20	17	11	10
Shares Outstanding (Diluted, Weighted)(shares)	30	25	21	21	20	17	11	10
EBITDA	–	–	-28	-31	-28	-17	-13	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.8%
Operating margin: -185.3%
Net margin: -171.6%
Return on equity, FY2025: -67.1%

Financial strength

Current ratio: 6.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 420.0%

Valuation

P/E ratio: 4.2
Price to sales: 11.16
Price to book: 4.28
Dividend yield: –